Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459988 · ClinicalTrials.gov registry record
Mechanistic Study of Ocrevus
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 35
- Enrollment target
NCT04459988: Completed study, sponsored by University of Michigan.
NCT04459988 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04459988 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Primary Outcome
Percentage B cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2022-10-25 |
What the finished NCT04459988 record still lists
NCT04459988 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04459988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04459988 about?
NCT04459988 is a clinical study titled "Mechanistic Study of Ocrevus". The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in ...
What is the current status of trial NCT04459988?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2020-07-01. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT04459988?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04459988?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI